Spots Global Cancer Trial Database for immunogenicity
Every month we try and update this database with for immunogenicity cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox® | NCT02444572 | Gastrointestina... Thromboembolic ... | Enoxaparin 4000... | 19 Years - 90 Years | Les Laboratoires des Médicaments Stériles | |
| Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation | NCT01758367 | Recurrent Adult... | Deciatbine(DAC) | 18 Years - 60 Years | Chinese PLA General Hospital | |
| Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents | NCT00534638 | Infections, Pap... | Cervarix Engerix-B | 12 Years - 15 Years | GlaxoSmithKline | |
| Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors | NCT01031719 | H1N1 Influenza ... Invasive Solid ... | adjuvanted A(H1... non-adjuvanted ... non-adjuvanted ... | 2 Years - 70 Years | Chiltern Pesquisa Clinica Ltda | |
| Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies | NCT04878822 | Immunogenicity Hematological M... Covid-19 Vaccine Respons... | 18 Years - | Ospedale di Circolo - Fondazione Macchi | ||
| A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence | NCT02334735 | Melanoma | DC Vaccine Montanide Vacci... Poly-ICLC | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma | NCT03528629 | Gastric Cancer Gastro-esophage... | Zolbetuximab | 20 Years - | Astellas Pharma Inc | |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | NCT02573259 | Part 1 MELANOMA SCCHN OVCA SARCOMA OTHER SOLID TUM... Part 1 and 2 NSCLC UROTHELIAL CARC... | PF-06801591 PF-06801591 | 18 Years - | Pfizer | |
| Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old, An Exploratory Immunogenicity Study | NCT05329961 | Human Papilloma... | Gardasil9 | 4 Years - 8 Years | Boston Medical Center | |
| Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation | NCT01758367 | Recurrent Adult... | Deciatbine(DAC) | 18 Years - 60 Years | Chinese PLA General Hospital | |
| Alternate Dosing Schedules Study for HPV Vaccine (ADS) | NCT02280642 | Cervical Cancer Genital Warts | Both 2nd and 3r... 2nd dose late a... 2nd dose on tim... Both doses late | 9 Years - 18 Years | Duke University | |
| The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine | NCT05279248 | Human Papilloma... Human Papilloma... Measles Rubella Mumps | HPV+MMR（0d），HPV... HPV（0d），HPV（6m）... MMR（0d），HPV（1m）... | 13 Years - 14 Years | Zhejiang Provincial Center for Disease Control and Prevention | |
| Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox® | NCT02444572 | Gastrointestina... Thromboembolic ... | Enoxaparin 4000... | 19 Years - 90 Years | Les Laboratoires des Médicaments Stériles | |
| Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia | NCT00924170 | Adult T-Cell Le... | LMB-2 Fludarabine Cyclophosphamid... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma | NCT03223103 | Glioblastoma | Poly-ICLC Tumor Treating ... Peptides | 18 Years - | Albert Einstein College of Medicine | |
| Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease | NCT05599347 | Crohn's Disease... Biological Subs... | Azithromycin Pi... Placebo | 18 Years - | Rambam Health Care Campus | |
| Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females | NCT01031069 | Infections, Pap... Papillomavirus ... | GSK Biologicals... Merck's Human P... | 15 Years - 25 Years | GlaxoSmithKline | |
| Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients | NCT03172377 | Crohn Disease i... Crohn Disease | Lengthening ada... | 18 Years - | Radboud University Medical Center | |
| An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen | NCT04206813 | HPV Infection | Gardasil 9 2 do... Gardasil 9 3 do... Gardasil 9 resc... | 16 Years - 45 Years | Boston Medical Center | |
| An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen | NCT04206813 | HPV Infection | Gardasil 9 2 do... Gardasil 9 3 do... Gardasil 9 resc... | 16 Years - 45 Years | Boston Medical Center | |
| Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy | NCT06375915 | Intrahepatic Ch... | radioembolizati... Durvalumab Cisplatin Gemcitabine | 18 Years - 80 Years | IRCCS San Raffaele | |
| Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age | NCT04782895 | Cervical Cancer Condylomata Acu... | Recombinant Hum... Gardasil®9 | 18 Years - 26 Years | Xiamen University | |
| Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma | NCT00928902 | Melanoma | low-dose IL-2 melanoma vaccin... | 18 Years - 85 Years | University of Virginia | |
| COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients | NCT05054218 | Covid19 SARS-CoV2 Infec... | mRNA-1273 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML） | NCT01690507 | MDS AML | Decitabine Cytarabine aclacinomycin Granulocyte col... HLA haploidenti... | 55 Years - 75 Years | Chinese PLA General Hospital | |
| Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox® | NCT02444572 | Gastrointestina... Thromboembolic ... | Enoxaparin 4000... | 19 Years - 90 Years | Les Laboratoires des Médicaments Stériles | |
| Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs | NCT00541970 | Infections, Pap... | Cervarix Placebo | 9 Years - 25 Years | GlaxoSmithKline | |
| Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer | NCT03511378 | Breast Cancer | Lupin's Pegfilg... Neulasta® | 18 Years - | Lupin Ltd. | |
| Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients | NCT02116504 | Rheumatoid Arth... Juvenile Idiopa... | Sampling of blo... | 2 Years - | Assistance Publique - Hôpitaux de Paris | |
| Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy | NCT06375915 | Intrahepatic Ch... | radioembolizati... Durvalumab Cisplatin Gemcitabine | 18 Years - 80 Years | IRCCS San Raffaele | |
| Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies | NCT04878822 | Immunogenicity Hematological M... Covid-19 Vaccine Respons... | 18 Years - | Ospedale di Circolo - Fondazione Macchi | ||
| Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old, An Exploratory Immunogenicity Study | NCT05329961 | Human Papilloma... | Gardasil9 | 4 Years - 8 Years | Boston Medical Center | |
| Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age | NCT04782895 | Cervical Cancer Condylomata Acu... | Recombinant Hum... Gardasil®9 | 18 Years - 26 Years | Xiamen University | |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | NCT02573259 | Part 1 MELANOMA SCCHN OVCA SARCOMA OTHER SOLID TUM... Part 1 and 2 NSCLC UROTHELIAL CARC... | PF-06801591 PF-06801591 | 18 Years - | Pfizer | |
| Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents | NCT00534638 | Infections, Pap... | Cervarix Engerix-B | 12 Years - 15 Years | GlaxoSmithKline | |
| Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals | NCT04871165 | Hematologic Neo... COVID-19 Vaccin... | S-binding IgG, ... Assessment of p... Quantitative se... | 12 Years - | Vilnius University | |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy | NCT01798056 | Herpes Zoster Herpes Zoster V... | GSK 1437173A Placebo | 18 Years - | GlaxoSmithKline | |
| MEDI5752 in Japanese Patients With Advanced Solid Tumors. | NCT05685472 | Advanced Solid ... | MEDI5752 | 18 Years - 120 Years | AstraZeneca | |
| Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients | NCT02116504 | Rheumatoid Arth... Juvenile Idiopa... | Sampling of blo... | 2 Years - | Assistance Publique - Hôpitaux de Paris | |
| Alternate Dosing Schedules Study for HPV Vaccine (ADS) | NCT02280642 | Cervical Cancer Genital Warts | Both 2nd and 3r... 2nd dose late a... 2nd dose on tim... Both doses late | 9 Years - 18 Years | Duke University | |
| Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) | NCT02638090 | Lung Cancer Non-small Cell ... | Vorinostat Pembrolizumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine | NCT05279248 | Human Papilloma... Human Papilloma... Measles Rubella Mumps | HPV+MMR（0d），HPV... HPV（0d），HPV（6m）... MMR（0d），HPV（1m）... | 13 Years - 14 Years | Zhejiang Provincial Center for Disease Control and Prevention | |
| Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients | NCT02116504 | Rheumatoid Arth... Juvenile Idiopa... | Sampling of blo... | 2 Years - | Assistance Publique - Hôpitaux de Paris | |
| A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma | NCT03528629 | Gastric Cancer Gastro-esophage... | Zolbetuximab | 20 Years - | Astellas Pharma Inc | |
| Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers | NCT01767467 | Herpes Zoster | Herpes zoster v... Placebo | 18 Years - | GlaxoSmithKline | |
| Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers | NCT01767467 | Herpes Zoster | Herpes zoster v... Placebo | 18 Years - | GlaxoSmithKline | |
| Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs | NCT00541970 | Infections, Pap... | Cervarix Placebo | 9 Years - 25 Years | GlaxoSmithKline | |
| Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation | NCT01758367 | Recurrent Adult... | Deciatbine(DAC) | 18 Years - 60 Years | Chinese PLA General Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
